Company intelligence

ENVB

Enveric Biosciences, Inc. · NASDAQ · Healthcare

Price$1.46+3.55% · +$0.05

Market cap871.64KEquity value

P / E-0.1Trailing ratio

Volume61.73KLatest session

Market data

ENVB price chart

TradingView

Related signals

1 min delayed

Browse public ENVB signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ENVBAug 5, 2026-1.88% since signal

Enveric's EB-003 Non-Hallucinogenic Profile Supports Phase 1 Push

Enveric Biosciences reports EB-003 exhibits a non-hallucinogenic signaling profile in sensitive assays, aligned with recent research differentiating hallucinogens from non-hallucinogens. If this holds in humans, EB-003 could ease psychedelic-therapy regulatory requirements and speed development. The stock declined about 7.7% premarket to $1.56 amid mixed sentiment.

View signal analysis

ENVBApr 24, 2026+2.90% since signal

FDA's Accelerated Action Boosts Enveric Biosciences Stock Performance

Enveric Biosciences (ENVB) saw an uptick in its stock price following the FDA's acceleration of actions regarding psychedelics as viable treatments. This regulatory support could enhance investment opportunities and partnerships in the psychedelic space, potentially benefiting ENVB’s market position.

View signal analysis

ENVBApr 20, 2026-10.61% since signal

Enveric Shares Surge Amid U.S. Psychedelic Regulatory Changes

Enveric Biosciences has seen a dramatic surge of over 92% following a recent U.S. executive order aimed at accelerating the review processes for psychedelic therapies. This regulatory shift, along with a significant federal investment in ibogaine research, could substantially enhance Enveric's market opportunities in the short term.

View signal analysis

Research